Marcela V. Maus, Ph.D.
Affiliations: | University of Pennsylvania, Philadelphia, PA, United States |
Google:
"Marcela Maus"Parents
Sign in to add mentor| Carl H. June | grad student | 2003 | Penn | |
| (Biology of human T cell activation.) | ||||
Children
Sign in to add trainee| Sangwoo Park | post-doc | 2024- | Harvard Medical School & Massachuestts General Hospital (Chemistry Tree) |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Silva H, Martin G, Birocchi F, et al. (2024) CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual targeting antibody overcome antigen heterogeneity in AML. Blood |
| Kaulen LD, Karschnia P, Doubrovinskaia S, et al. (2024) Toxicities and outcome after CD19-directed chimeric antigen receptor T-cell therapy for secondary neurolymphomatosis. American Journal of Hematology |
| Minguet S, Maus MV, Schamel WW. (2024) From TCR fundamental research to innovative chimeric antigen receptor design. Nature Reviews. Immunology |
| Blumenberg V, Maus MV. (2024) Tracking non-relapse mortality after CAR T cell therapy. Nature Medicine |
| Korell F, Olson ML, Salas-Benito D, et al. (2024) Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics. Science Translational Medicine. 16: eadk7640 |
| Frigault MJ, Graham CE, Berger TR, et al. (2024) Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies. Blood |
| Perez CR, Garmilla A, Nilsson A, et al. (2024) Library-based single-cell analysis of CAR signaling reveals drivers of persistence. Biorxiv : the Preprint Server For Biology |
| Ormhøj M, Scarfò I, Cabral ML, et al. (2024) Correction: Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 30: 2286 |
| Grauwet K, Berger T, Kann MC, et al. (2024) Stealth transgenes enable CAR-T cells to evade host immune responses. Journal For Immunotherapy of Cancer. 12 |
| Walton ZE, Frigault MJ, Maus MV. (2024) Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy. Expert Opinion On Pharmacotherapy. 25: 263-279 |